Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers

Jhih Ying Chi, Yu Wei Hsiao, Chien Feng Li, Yu-Chih Lo, Zu Yau Lin, Jhen Yi Hong, Yang Ming Liu, Xiu Han, Shao Ming Wang, Ben-Kuen Chen, Kelvin K. Tsai, Ju-Ming Wang

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The tumor microenvironment has been suggested to participate in tumorigenesis, but the nature of the communication between cancer cells and the microenvironment, especially in response to anticancer drugs, remains obscure. We determined that activation of the CCAAT/enhancer binding protein delta (CEBPD) response to Cisplatin and 5-Fluorouracil in cancer-associated macrophages and fibroblasts contributed to the metastasis, invasion, acquired chemoresistance and stemness of cancer cells by in vitro and in vivo assays. Specifically, reporter and in vivo DNA binding assays were used to determine that Pentraxin 3 (PTX3) is a CEBPD responsive gene and serves a protumor role upon anticancer drug treatment. Finally, a PTX3 peptide inhibitor RI37 was developed and assessed the antitumor effects by in vivo assays. RI37 could function as a promising inhibitor for preventing cancer progression and the metastasis, invasion and progression of drug-resistant cancers. The identification of PTX3 provided a new insight in the interaction between host and tumor and the RI37 peptide showed a great opportunity to largely reduce the risk of invasion and metastasis of cancer and drug-resistant cancers.

Original languageEnglish
Pages (from-to)23987-24001
Number of pages15
JournalOncotarget
Volume6
Issue number27
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Drug Therapy
CCAAT-Enhancer-Binding Protein-delta
Pharmaceutical Preparations
Neoplasms
Tumor Microenvironment
Neoplasm Metastasis
Cellular Microenvironment
Peptides
Fluorouracil
Cisplatin
PTX3 protein
Carcinogenesis
Macrophages
DNA
Genes
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Chi, Jhih Ying ; Hsiao, Yu Wei ; Li, Chien Feng ; Lo, Yu-Chih ; Lin, Zu Yau ; Hong, Jhen Yi ; Liu, Yang Ming ; Han, Xiu ; Wang, Shao Ming ; Chen, Ben-Kuen ; Tsai, Kelvin K. ; Wang, Ju-Ming. / Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers. In: Oncotarget. 2015 ; Vol. 6, No. 27. pp. 23987-24001.
@article{7189e0eed2db4cc3ac3783ff0ff15846,
title = "Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers",
abstract = "The tumor microenvironment has been suggested to participate in tumorigenesis, but the nature of the communication between cancer cells and the microenvironment, especially in response to anticancer drugs, remains obscure. We determined that activation of the CCAAT/enhancer binding protein delta (CEBPD) response to Cisplatin and 5-Fluorouracil in cancer-associated macrophages and fibroblasts contributed to the metastasis, invasion, acquired chemoresistance and stemness of cancer cells by in vitro and in vivo assays. Specifically, reporter and in vivo DNA binding assays were used to determine that Pentraxin 3 (PTX3) is a CEBPD responsive gene and serves a protumor role upon anticancer drug treatment. Finally, a PTX3 peptide inhibitor RI37 was developed and assessed the antitumor effects by in vivo assays. RI37 could function as a promising inhibitor for preventing cancer progression and the metastasis, invasion and progression of drug-resistant cancers. The identification of PTX3 provided a new insight in the interaction between host and tumor and the RI37 peptide showed a great opportunity to largely reduce the risk of invasion and metastasis of cancer and drug-resistant cancers.",
author = "Chi, {Jhih Ying} and Hsiao, {Yu Wei} and Li, {Chien Feng} and Yu-Chih Lo and Lin, {Zu Yau} and Hong, {Jhen Yi} and Liu, {Yang Ming} and Xiu Han and Wang, {Shao Ming} and Ben-Kuen Chen and Tsai, {Kelvin K.} and Ju-Ming Wang",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.4364",
language = "English",
volume = "6",
pages = "23987--24001",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "27",

}

Chi, JY, Hsiao, YW, Li, CF, Lo, Y-C, Lin, ZY, Hong, JY, Liu, YM, Han, X, Wang, SM, Chen, B-K, Tsai, KK & Wang, J-M 2015, 'Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers', Oncotarget, vol. 6, no. 27, pp. 23987-24001. https://doi.org/10.18632/oncotarget.4364

Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers. / Chi, Jhih Ying; Hsiao, Yu Wei; Li, Chien Feng; Lo, Yu-Chih; Lin, Zu Yau; Hong, Jhen Yi; Liu, Yang Ming; Han, Xiu; Wang, Shao Ming; Chen, Ben-Kuen; Tsai, Kelvin K.; Wang, Ju-Ming.

In: Oncotarget, Vol. 6, No. 27, 01.01.2015, p. 23987-24001.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers

AU - Chi, Jhih Ying

AU - Hsiao, Yu Wei

AU - Li, Chien Feng

AU - Lo, Yu-Chih

AU - Lin, Zu Yau

AU - Hong, Jhen Yi

AU - Liu, Yang Ming

AU - Han, Xiu

AU - Wang, Shao Ming

AU - Chen, Ben-Kuen

AU - Tsai, Kelvin K.

AU - Wang, Ju-Ming

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The tumor microenvironment has been suggested to participate in tumorigenesis, but the nature of the communication between cancer cells and the microenvironment, especially in response to anticancer drugs, remains obscure. We determined that activation of the CCAAT/enhancer binding protein delta (CEBPD) response to Cisplatin and 5-Fluorouracil in cancer-associated macrophages and fibroblasts contributed to the metastasis, invasion, acquired chemoresistance and stemness of cancer cells by in vitro and in vivo assays. Specifically, reporter and in vivo DNA binding assays were used to determine that Pentraxin 3 (PTX3) is a CEBPD responsive gene and serves a protumor role upon anticancer drug treatment. Finally, a PTX3 peptide inhibitor RI37 was developed and assessed the antitumor effects by in vivo assays. RI37 could function as a promising inhibitor for preventing cancer progression and the metastasis, invasion and progression of drug-resistant cancers. The identification of PTX3 provided a new insight in the interaction between host and tumor and the RI37 peptide showed a great opportunity to largely reduce the risk of invasion and metastasis of cancer and drug-resistant cancers.

AB - The tumor microenvironment has been suggested to participate in tumorigenesis, but the nature of the communication between cancer cells and the microenvironment, especially in response to anticancer drugs, remains obscure. We determined that activation of the CCAAT/enhancer binding protein delta (CEBPD) response to Cisplatin and 5-Fluorouracil in cancer-associated macrophages and fibroblasts contributed to the metastasis, invasion, acquired chemoresistance and stemness of cancer cells by in vitro and in vivo assays. Specifically, reporter and in vivo DNA binding assays were used to determine that Pentraxin 3 (PTX3) is a CEBPD responsive gene and serves a protumor role upon anticancer drug treatment. Finally, a PTX3 peptide inhibitor RI37 was developed and assessed the antitumor effects by in vivo assays. RI37 could function as a promising inhibitor for preventing cancer progression and the metastasis, invasion and progression of drug-resistant cancers. The identification of PTX3 provided a new insight in the interaction between host and tumor and the RI37 peptide showed a great opportunity to largely reduce the risk of invasion and metastasis of cancer and drug-resistant cancers.

UR - http://www.scopus.com/inward/record.url?scp=84943417989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943417989&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.4364

DO - 10.18632/oncotarget.4364

M3 - Article

VL - 6

SP - 23987

EP - 24001

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 27

ER -